Effects of Vaccine Preservatives and Adjuvants on Childhood Neurodevelopment by Raveh, Reut
The Science Journal of the Lander College of Arts and Sciences 
Volume 9 
Number 2 Spring 2016 Article 6 
1-1-2016 
Effects of Vaccine Preservatives and Adjuvants on Childhood 
Neurodevelopment 
Reut Raveh 
Touro College 
Follow this and additional works at: https://touroscholar.touro.edu/sjlcas 
 Part of the Developmental Neuroscience Commons, and the Immunoprophylaxis and Therapy 
Commons 
Recommended Citation 
Raveh, R. (2016). Effects of Vaccine Preservatives and Adjuvants on Childhood Neurodevelopment. The 
Science Journal of the Lander College of Arts and Sciences, 9 (2). Retrieved from 
This Article is brought to you for free and open access by the Lander College of Arts and Sciences at Touro Scholar. 
It has been accepted for inclusion in The Science Journal of the Lander College of Arts and Sciences by an 
authorized editor of Touro Scholar. For more information, please contact Timothy J Valente 
timothy.valente@touro.edu. 
149
Introduction
Thimerosal, a mercury-based vaccine preservative, has been a 
source of controversy since the 1990’s. Many parents worried 
that the presence of mercury in vaccinations could lead to au-
tism spectrum disorder and other medical problems. The Center 
for Disease Control and the American Academy of Pediatrics 
collectively decided, in July 1999, to remove thimerosal con-
taining vaccines (Baker, 2007).  According to the Food and Drug 
Administration thimerosal has undergone various studies and it 
“has a long record of safe and effective use preventing bacterial 
and fungal contamination of vaccines, with no ill effects estab-
lished other than minor local reactions at the site of injection” 
(FDA, 2015). In the United States, the only vaccines that currently 
contain thimerosal are MPSV4-Menomune (vaccine for menin-
gitis), Td (booster for tetanus and dipthereia) manufactured by 
Decavac, Td (Mass Biologics), Dt (Sanofi) and three of the influen-
za vaccines (Hamborsky et al., 2015). Some researchers posit that 
there may be a link between thimerosal and neurodevelopmental 
problems. Other studies demonstrate that thimerosal does not 
have such effects. This study was done to determine if thimerosal 
poses a risk on childhood neurodevelopment.
Purpose of Preservatives and Adjuvants in Vaccines:
The United States Code of Federal Regulations (CFR) mandates 
the addition of preservatives to vaccines in vials containing 
multiple doses to prevent contamination of the vaccine after 
multiple needle insertions. Previously, some vaccines became 
contaminated during the manufacturing process. As a result, the 
CFR required the addition of preservatives to kill the microbes 
that contaminated the vaccine. With the advancement of aseptic 
manufacturing of vaccines, the necessity of putting preservatives 
in vaccines has decreased. As a result, many vaccines do not 
currently require the addition of preservatives into them (Geier 
et al., 2010). Adjuvants are added to vaccines to help the body 
develop immunity after injection of killed vaccines. Adjuvants 
are added to minimize the amount of antigens the body needs 
to be exposed to in order to generate an immune response 
(Petrovsky, Aguilar, 2004).
Methyl Mercury vs. Ethyl Mercury
The main question behind the debate over thimerosal is the 
comparison between ethyl and methyl mercury. Mercury expo-
sure has been found to cause severe health problems such as 
damage to the nervous, digestive and immune systems. Methyl 
mercury specifically has been found to affect the developing 
brain and nervous system. The most susceptible individuals 
to methyl mercury are fetuses exposed to methyl mercury in 
utero (WHO, 2013). Methyl mercury has been proven to cause 
neurotoxicity since the 1960’s. Mothers who ate fish in water 
contaminated by methyl mercury during their pregnancy, gave 
birth to children with mental retardation, blindness, and spas-
ticity. However, mothers exposed to methyl mercury were less 
adversely affected than the infants. A study on New Zealand 
neonates born from mothers who had hair concentrations of 
mercury greater than six micrograms per gram found that in-
fants with greater mercury exposure had a lower Intelligence 
Quotient (IQ) by three points. The United States National 
Academy of Sciences decided that fetal exposure to methyl 
mercury can be toxic even at low concentrations (Grandjean, 
Landrigan, 2006). 
The Food and Drug Administration states that the legal guide-
lines for mercury exposure were decided based on studies 
on methyl mercury. However, thimerosal’s derivative is ethyl 
mercury which as a result of being slightly chemically differ-
ent can have different effects on the body than methyl mer-
cury. Additionally, high levels of ethyl mercury were found to 
have severe neurological effects on both adults and children. 
However, the effects of low dose ethyl mercury exposure have 
not been determined (Offit, Jew, 2003). As there is no definitive 
study with a safe exposure concentration of ethyl mercury and 
the differences in the effects of methyl and ethyl mercury are 
not known, the FDA considers ethyl mercury to be as toxic 
as methyl mercury (FDA, 2015).  Ethyl mercury was found to 
increase the tissue concentration of inorganic mercury more 
than methyl mercury does in rhesus macaques (Hornig et al., 
2004). Ethyl mercury levels in the brain post exposure are lower 
than those of methyl mercury (Clements, 2004). A main source 
of the controversy on thimerosal is the question if methyl and 
ethyl mercury have the same or different effects on the body. 
Some studies show that thimerosal’s ethyl mercury does indeed 
have neurotoxic effects, while others argue that it does not.
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Methods
A variety of research papers on the subject were collected from 
Google Scholar, EBSCO and ProQuest. Access to EBSCO and 
ProQuest was given through the Touro College Library System. 
Key words used, were thimerosal, neurodevelopment, adjuvants, 
vaccines, adverse effects and immunizations.
Results
Thimerosal and Neurodevelopment:  
Thimerosal Causes Neurodevelopmental Disorders
In the 1990’s many infants had mercury exposure higher than 
that recommended by the EPA, FDA, and the United States 
Agency for Toxic Substances and Disease Registry (ATSDR) for 
methyl mercury. This was a result of both Thimerosal Containing 
Vaccine (TCV) and environmental exposure. Methyl mercury is 
a compound that is closely related to ethyl mercury, one of 
the derivatives of thimerosal. A study of 278,624 infants born 
between 1990 and 1996 and recorded in the Vaccine Safety 
Datalink was done in order to determine if thimerosal indeed 
has neurotoxic effects on infants and young children. During 
those years the main vaccines containing thimerosal were the 
Haemophilus Influenza Type b (Hib), hepatitis B, acellular DTaP 
(Diptheria, Tetanus, acellular Pertussis), and whole-cell DTP. The 
amount of mercury exposure was calculated for each individual 
based on the amount and concentration of mercury in each 
of the mercury containing vaccines. The mercury exposure was 
measured between two intervals, birth and 7 months and birth 
and 13 months. The rate of increase in six neurodevelopmental 
disorders were calculated for each additional 100 microgram of 
mercury the children were exposed to. Three control disorders 
were also observed for each 100 microgram increase in mer-
cury exposure due to thimerosal containing vaccines. (Young et 
al., 2008)
The six neurodevelopmental disorders observed were Autism, 
Autism Spectrum Disorders (ASD), Hyperkinetic syndrome of 
childhood (ADD/ADHD), Developmental/Learning Disorders, 
Disturbances of emotions specific to childhood and adoles-
cence, and tics. The control disorders observed were pneumo-
nia, congenital anomalies, and failure to thrive. The study de-
termined that the ratios of each of these disorders increased 
with the increased exposure to Thimerosal containing vaccines. 
The rate ratios were measured with a confidence interval of 
95%.  For each 100 microgram increase in mercury exposure 
the ratio of hyperkinetic syndrome of childhood increased by 
a ratio of 3.15 and Autism and Autism Spectrum disorders in-
creased by ratios of 2.87 and 2.44 respectively. Developmental 
and Learning disorders had the lowest ratio of increase, while 
hyperkinetic syndrome had the highest. The control disorders 
did not have a relatively high increase as a result of higher mer-
cury exposure (Young et al., 2008). 
The levels of autism corresponding to each year in the study 
directly correlated to the amount of mercury exposure via vac-
cine. In 1990 and 1991, hepatitis B and Hib had been added 
to the vaccine schedule. After 1992, the DTP vaccine was 
combined with Hib vaccine, thus leading to a lower mercury 
exposure than there had been when the two vaccines were 
kept separate. The levels of autism in those years fluctuate di-
rectly with the fluctuations of mercury administered via vaccine 
(Young et al., 2008). 
Another study compared the toxicities of the four most com-
mon preservatives added to vaccines in the United States. These 
four compounds were 2-phenoxyphenol, phenol, Thimerosal, 
and benzethonium chloride. These compounds were admin-
istered to human neurons in vitro and to bacterial cells. The 
toxicities to each type of cell were measured. The cytotoxic-
ity towards human neuroblastoma cells was measured after 
24 hours of incubation. Thimerosal was found to be the most 
toxic of the four preservatives added to vaccines. Each of the 
four compounds was also tested on bacterial cells. A thimerosal 
concentration of ten times the amount added to vaccines was 
not able to sufficiently kill bacterial cells within twenty minutes 
(Geier et al., 2010).
While there is room to question the certainty of the thimero-
sal’s effects on children, it his highly likely that thimerosal does 
adversely affect the neurodevelopment of susceptible infants. In 
some of the studies thimerosal was the only measured vari-
able, while in others thimerosal was taken into account with 
other possible neurotoxic environmental exposures. Using the 
Gesell Development Score, investigators found no correlation 
between thimerosal exposure from vaccines and neurodevel-
opmental disorders, if the child nursed for the first six months 
of life. The GDS was also measured from birth to five years 
and once again there was no correlation between thimerosal 
exposure and neurodevelopmental disorders. The studies that 
took environmental exposure to neurotoxic elements into con-
sideration as well as thimerosal, found that ethyl mercury, one 
of the byproducts of thimerosal, has adverse effects on neuro-
development. The controlled variables were the environmental 
factors that were known to affect neuroplasticity. For example, 
secondhand smoke, cord blood Hg, and lead (Dorea, 2015).
The Vaccine Adverse Events Reposting System (VAERS) da-
tabase was used to determine if indeed the rise in childhood 
neurodevelopmental disorders was caused by thimerosal ex-
posure due to vaccinations. A comparison was made of the 
prevalence of neurodevelopmental disorders after exposure 
to either thimerosal containing or thimerosal free DTaP vac-
cines. Three neurodevelopmental disorders were observed in 
this study; autism, personality disorders and mental retardation. 
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The participating patients were split into two groups, the first 
group had an average mercury exposure of 37.5 microgram, 
while the second group had a mercury exposure of 87.5 micro-
grams. Some of the control adverse events were fever, pain, and 
vomiting. The United States Department of Education report 
from 2001 was also evaluated to find out how many children 
in different age groups suffered from a variety of conditions; 
autism, speech disorders, orthopedic or visual impairments, and 
deaf-blindness. The amount of mercury the children were ex-
posed to was also compared to the maximum possible amount 
of mercury exposure allowed by the FDA (Geier, Geier, 2003).
Comparing the prevalence of autism, personality disorders and 
mental retardation following exposure to thimerosal from the 
DTaP vaccine and the thimerosal-free DTaP demonstrated a 
linear correlation between mercury exposure and neurode-
velopmental disorders. The odds ratio of autism increased by 
.029, personality disorders by .012, and mental retardation by 
.048 for each microgram of mercury. The odds ratio for each 
of these disorders was higher for each of them after exposure 
to the DTaP containing thimerosal than for that without it. 
The United States Department of Education report also had 
increasing ratios in autism and speech disorders. The amount 
of febrile seizure, fever, pain, edema, and vomiting was higher 
for the thimerosal containing DTaP vaccine group, however the 
amount it rose and the increasing amount of mercury exposure 
do not directly relate to one another. The study also demon-
strated that the amount of mercury the children were exposed 
to due to the childhood vaccine schedule in different years had 
3.2-32 fold higher amount than that recommended by the FDA 
for oral methylmercury. Exposure to mercury intravenously has 
more adverse effects on the body than if it has been orally in-
gested (Geier, Geier, 2003).
A study surveying British children found there to be a rela-
tionship between hyperactivity and behavioral problems, motor 
development and the necessity for speech therapy. Other stud-
ies have found that there were significant differences in the 
impact of thimerosal on different genders. Male children were 
found to have a higher IQ upon exposure, but the exposure 
also hampered their behavioral regulation and motor tics. In a 
study in Italian children thimerosal was found to detrimentally 
affect girls in the areas of language and motor function (Curtis 
et al., 2015) 
An overview was done by analyzing the results of in vivo and in 
vitro studies of the thimerosal’s effects. In the in vitro studies 
thimerosal was found to cause mitochondrial damage, reduce 
oxidation-reduction activity, cause cell degeneration and cell 
death, and increase the levels of fragmented DNA in human 
neuroblastoma cells. In some of the overviewed studies the 
concentration of thimerosal tested was lower than that found 
in TCV, while in some the concentration ranged from nano 
to micromolar concentrations. An In vivo study administered 
different concentrations of thimerosal to suckling Wistar and 
Lewis rats at 7, 9, 11 and 15 days. The thimerosal was found to 
decrease pain sensitivity and to significantly accumulate in rat 
brains. The concentration of thimerosal found in vaccines had 
neurotoxic effects on human neurons in vitro and in laboratory 
animals (Dorea, 2011). 
Thimerosal Does Not Cause 
Neurodevelopmental Disorders
A study was done in Poland to determine if there is a correla-
tion between exposure to Thimerosal containing vaccines and 
cognitive development in the children’s’ first nine years. All of 
these children had been given the DTP and hepatitis B vaccine, 
some of which contained thimerosal and some which didn’t. 
At different points during the first nine years of life, tests were 
done to assess the level of each child’s cognitive development. 
All the vaccines that the children were exposed to contained 
aluminum as an adjuvant. In the first month of life 69.2% of 
the children were exposed to thimerosal, and between the first 
month and the 6th month 86.2% of the children were exposed 
to thimerosal containing vaccines. The results of each psycho-
logical test done were similar for both children who were and 
were not exposed to thimerosal. In fact the IQ levels of those 
exposed to thimerosal was higher overall than that of the con-
trol group. The results of the study displayed no correlation be-
tween thimerosal exposure and lower cognitive developmental 
levels. (Mrozek-Budzyn et al., 2014). 
Various studies had been done testing thimerosal containing 
vaccines on rodents, with results demonstrating that thimerosal 
had no neurodevelopmental effects. However, on the rare occa-
sion that there was a problem with the vaccine, a very high dos-
age of thimerosal had been administered, 250 fold higher than 
contained in vaccines. A study was done to compare the effects 
of different vaccine schedules on a non-human primate model. 
These were chosen as their anatomy and length of development 
stages are very similar to those of humans. Neurobehavioral 
tests were done on the primates to see the effect of a variety of 
vaccine schedules on the primates’ neurodevelopment (Curtis 
et al., 2015).
In the study seventy-nine rhesus macaques were split into six 
groups. The first group, the control, received saline injections. 
The second group received only the MMR vaccine, the third 
TCV’s excluding the MMR vaccine. The fourth group was ad-
ministered the vaccine schedule from the 1990’s, while the fifth 
group received the same vaccines with accelerated timing at 
a ratio of 4:1. The sixth group was administered the vaccine 
152
Reut Raveh
schedule from 2008. In the 1999 vaccine schedule, the TCV’s 
were Hepatitis B, DTaP, and Hib. In the 2008 vaccine schedule, 
the multiple-dose influenza and meningitis vaccines contained 
thimerosal. The pregnant macaques in the 2008 group were 
given the influenza vaccines a month before the expected deliv-
ery date. (Curtis et al., 2015).
Each of the infant macaques was tested on the Neonatal 
Behavioral Assessment Scale to check for nineteen neonatal 
reflexes. There was no significant difference in the results of 
each of the six groups for the NBAS test, except in one of the 
criteria. The macaques were also tested for their object con-
cept performance, their social behavior and the discrimination/
reversal learning and learning set. In each of these tests there 
were no significant differences in the results among the groups. 
The animals given TCVs reached their goal in fewer trials than 
animals in the control group in the reversal learning part of 
the test. Thereby demonstrating that thimerosal did not hamper 
this area of neurodevelopment. At the age of 12 months the fifth 
group had a significantly lower amount of exploring behaviors 
than did the control macaques. The fifth group also had a lower 
amount of positive behaviors at 2 months, while at 12 months 
they had a higher amount of positive behaviors than did the rest 
at two months of age the fourth and sixth groups had signifi-
cantly fewer negative behaviors, however at 12 months there 
were no major differences between the six groups (Curtis et 
al., 2015).
A study in Denmark, used data from the Danish Psychiatric 
Central Research Register to determine if thimerosal expo-
sure leads to autism spectrum disorder. This study was done to 
determine if removing thimerosal from vaccines decreased the 
incidence of autism. The rates of autism diagnosed from 1971 
to 2000 for children in three age groups, ages 2-4, 5-6, and 7-9, 
were reviewed. From the years 1961 to 1970 the children were 
administered 400 micrograms of thimerosal. From 1971-1992 
children were exposed to 250 micrograms of thimerosal.  After 
1992, vaccines without thimerosal were administered to Danish 
children. During this period, 956 children had been diagnosed 
with autism. From 1971 to about 1990 the rates of autism re-
mained stable. After 1991, the rates of autism began to increase, 
peaking in the year 1999 with the highest incidences occurring 
in the first two age groups, between 2 – 6 years of age. Each 
of these children had been born after thimerosal containing 
vaccines had been removed from the Danish vaccine schedule. 
Thereby indicating, that the increase of autism does not relate 
to thimerosal exposure (Madsen et. al, 2003). 
Aluminum and Neurodevelopment
Studies have demonstrated that in vitro aluminum exposure has 
the potential to cause cell death in human neurons. However, 
aluminum has been found to be less cytotoxic than thimero-
sal (Dorea, Marques, 2009). A study was done to determine if 
aluminum exposure as a result of its use as a vaccine adjuvant 
is a cause of the rise of autism. Data was taken from the US 
Department of Educational Annual Reports to Congress to de-
termine the rates of autism from 1991-2008 for individuals age 
6 – 21. The rates of autism were also compared to the aluminum 
exposure in regards to the vaccine schedule in other countries. 
The data was compared to the concentration of aluminum ex-
posure from pediatric vaccines, below 6 years of age. Results 
demonstrated that the highest level of aluminum in compari-
son was at age 2 months in the United States. Interestingly, the 
countries with higher aluminum adjuvant exposure had higher 
rate of autism (Tomljenovic, Shaw, 2011).
Discussion
Based on the reported studies there is room to question the 
effects of the Thimerosal and vaccines containing it on human 
children. Studies done in vitro demonstrate that thimerosal 
does cause apoptosis and neurotoxic effects to human neu-
rons (Dorea, 2011). However, results occurring in vitro are not 
always a directly comparable to those in vivo, as in vivo it is 
difficult to accurately evaluate the concentration of mercury 
reaching the individual’s neurons. Additionally, studies done 
on Rhesus macaques seem to point out that thimerosal does 
not hinder neurodevelopment, in some cases the exposed an-
imals had scored higher than the control (Curtis et al., 2015). 
However, the primate model is not necessarily an exact indica-
tion as to what would happen to humans when they would be 
exposed to the same concentrations of thimerosal, though the 
results would be similar as the two bodies function similarly. 
Only seventy-nine macaques were surveyed and then split into 
six groups, thereby only a small number of macaques represent-
ed each vaccine schedule. Therefore, even though the macaque 
functions similarly to humans, the validity of the results in com-
parison to human would need a higher number of macaques in 
each group to demonstrate the efficacy of the results. 
The study using the Vaccine Safety Datalink uses a large sample 
of children, and demonstrates a direct correlation between thi-
merosal exposure and neurodevelopmental disorders. However, 
the study does not take into account environmental exposure 
to mercury and other neurotoxins, thereby making it harder to 
say with certainty that thimerosal does indeed cause different 
neurodevelopmental disorders (Young et al., 2008). The study 
also does not take into account the genetics of the children and 
the possible predisposition to neurodevelopmental disorders. 
However, there does seem to be a strong indication that thi-
merosal has neurodevelopmental effects, as the prevalence of 
autism in various years was directly related to the fluctuations 
of mercury in the childhood vaccine schedule, thus indicating 
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that children born in years that a vaccine schedule with a higher 
concentration of mercury had increased rates of autism.
Additionally, the primate model is not a direct representation 
of what would happen in the human models because studies 
show that the rate of elimination in the blood and brain differ 
for methyl and ethyl mercury in primates and human infants 
(Hornig et al., 2004). As a result, ethyl mercury in humans may 
cause different mercury levels than it would for the rhesus ma-
caques used in two of the above studies. 
Based on the above studies it is hard to conclude whether or 
not thimerosal containing vaccines cause neurodevelopmental 
disorders. However, some studies do seem to indicate that thi-
merosal causes autism among other neurodevelopmental disor-
ders. Additionally, thimerosal containing vaccines were found to 
cause a significant amount of damage to human neurons in vitro, 
including cell death. As a result, further study must be done 
to determine with certainty the true effects of thimerosal on 
human neurodevelopment. 
As one study demonstrated that the concentration of thimer-
osal found in human vaccines was not sufficient to kill bac-
terial cells, the question arises as to the necessity of placing 
thimerosal into vaccines. Additionally, after administration of 
multiple does DTP and Td vaccines that contained thimerosal 
as a preservative there were outbreaks of pyogenic infections. 
Indicating that despite the addition of preservatives to vaccines, 
microbial contamination can still occur (Ball et all, 2001). One of 
the main vaccines today currently containing thimerosal is the 
multiple-dose influenza vaccine. Thimerosal is added as a preser-
vative to prevent bacterial contamination of the vaccine. If the 
concentration of thimerosal needed to effectively rid the vac-
cine of bacteria is higher than the concentration of thimerosal 
in the vaccine, then it is likely that the thimerosal is not doing its 
job. Steps should be taken to remove thimerosal from vaccines 
as there is a strong potential that thimerosal does indeed cause 
neurodevelopmental problems. If thimerosal is kept in vaccines, 
it should be determined whether the benefits thimerosal brings 
to the vaccine outweigh the risks brought onto children when 
they are vaccinated.
Fetuses, neonates, and other small children are the most sus-
ceptible to neurodevelopmental damage, as these are the peri-
ods of brain growth (WHO, 2013 and Dorea, 2015). The World 
Health Organizations states a fetus is the most susceptible to 
neurotoxic factors (WHO, 2016). Additionally, during the pre-
natal and early postnatal stages the Blood Brain Barrier (BBB) 
is not fully developed. As a result, the likelihood of neurotoxins 
crossing the BBB is higher in fetuses and newborns (Tomljenovic 
and Shaw, 2011). As the risks of thimerosal exist and there is 
not conclusive proof that there is not neurotoxicity, injecting 
pregnant woman and babies with vaccines containing thimerosal 
should be avoided, as these are the ages most critical to child-
hood neurodevelopment. For example, the Center for Disease 
Control currently recommends that the influenza vaccine be 
administered to pregnant woman as a woman suffering from in-
fluenza during her pregnancy is at great risk (Center for Disease 
Control, 2015). Pregnant woman are more likely to have longer 
stays at the hospital as a result of respiratory illnesses, than 
when not pregnant (American College of Obstetricians and 
Gynecologists). There seems to be a clear benefit of a pregnant 
woman being immunized to influenza. However, based on the 
information above, there is clearly a potential that thimerosal 
causes neurodevelopmental disorders, and this stage is where 
the fetus is the most susceptible to neurotoxins. As a result, 
measures should be taken to ensure that pregnant woman are 
given the influenza vaccine that does not contain thimerosal. 
Additionally, the postnatal stages till adolescence are still stages 
of neurodevelopment. As thimerosal potentially causes neuro-
developmental disorders, the benefits of thimerosal containing 
vaccines must be evaluated to see if they actually outweigh the 
risks presented by thimerosal exposure.
Conclusions
There is no definitive evidence to conclusively determine if 
thimerosal causes neurodevelopmental disorders in young 
children. However, the potential for thimerosal to cause neu-
rodevelopmental disorders gives rise to question the potential 
harm of the other agents used as preservatives and adjuvants 
in vaccine today. One of the main adjuvants used in vaccines 
today is Aluminum, which does seems to have the potential to 
affect neurodevelopment, specifically causing autism spectrum 
disorder. As vaccines are being administered to susceptible in-
dividuals, further studies should be done to all the chemicals 
added to vaccines to determine if they are really safe, and if the 
benefits they bring to the vaccine outweigh the risks.
References
American College of Obstetricians and Gynecologists. 
Influenza vaccination during pregnancy. Committee Opinion 
No. 608.Obstet Gynecol 2014;124:648–51.
Baker J. Mercury, Vaccines, and Autism. Am J Public Health. 
2008;98(2):244-253. doi:10.2105/ajph.2007.113159.
Ball LK, Ball R, Pratt RD. An Assessment of Thimerosal Use in 
Childhood Vaccines. Pediatrics 2001;107(5):1147–1154. doi:5 
May 2001.
book/downloads/appendices/B/excipient-table-2.pdf.
Centers for Disease Control and Prevention, 2015. Flu Vaccine 
Safety and Pregnancy. Available at: http://www.cdc.gov/flu/
154
Reut Raveh
protect/vaccine/qa_vacpregnant.htm. Accessed 2015.
Centers for Disease Control and Prevention, 2015. Pregnant 
Women & Influenza (Flu). Available at: http://www.cdc.gov/flu/
protect/vaccine/pregnant.htm. Accessed 2016.
Clements C.J. The evidence for the safety of thimerosal in 
newborn and infant vaccines. Vaccine. 2004;22:1854–1861. doi: 
10.1016/j.vaccine.2003.11.017
Curtis B, Liberato N, Rulien M et al. Examination of the Safety 
of Pediatric Vaccine Schedules in a Non-Human Primate 
Model: Assessments of Neurodevelopment, Learning, and 
Social Behavior. Environ Health Perspect. 2015. doi:10.1289/
ehp.1408257.
Dórea J. Exposure to Mercury and Aluminum in Early 
Life: Developmental Vulnerability as a Modifying Factor in 
Neurologic and Immunologic Effects. International Journal of 
Environmental Research and Public Health. 2015;12(2):1295-
1313. doi:10.3390/ijerph120201295.
Dórea J. Integrating Experimental (In Vitro and In Vivo) 
Neurotoxicity Studies of Low-dose Thimerosal Relevant to 
Vaccines. Neurochem Res. 2011;36(6):927-938. doi:10.1007/
s11064-011-0427-0.
Dórea JG, Marques RC. Infants’ exposure to aluminum from 
vaccines and breast milk during the first 6 months. Journal 
of Exposure Science and Environmental Epidemiology 
2009:598–601
Food and Drug Administration. Thimerosal in Vaccines. Fda.gov. 
2015. Available at:http://www.fda.gov/BiologicsBloodVaccines/
SafetyAvailability/VaccineSafety/UCM096228#t3. Accessed 
November 27, 2015.
Geier D, Jordan S, Geier M. The relative toxicity of compounds 
used as preservatives in vaccines and biologics. Med Sci Monit. 
2010;(16):SR21-27.
Geier DA, Geier MR. An assessment of the impact of thimer-
osal on childhood neurodevelopmental disorders. Pediatric 
Rehabiliation 2003;6(2):97–102.
Grandjean P, Landrigan P. Developmental neurotoxicity of 
industrial chemicals. The Lancet. 2006;368(9553):2167-2178. 
doi:10.1016/s0140-6736(06)69665-7.
Hamborsky J, Kroger A, Wolfe S Appendix B: Vaccine Excipient 
and Media Summary. In: Epidemiology And Prevention 
Of Vaccine-Preventable Diseases. Centers for Disease 
Control and Prevention.  13th ed. Washington D.C.: Public 
HealthFoundation; 2015:7-10.Availableat:http://www.cdc.gov/
vaccines/pubs/pink
Hornig M, Chian D, Lipkin W. Neurotoxic effects of postnatal 
thimerosal are mouse strain dependent. Molecular Psychiatry. 
2004;9(9):833-845. doi:10.1038/sj.mp.4001529.
Madsen KM, Lauritsen MB, Pedersen CB, et al. Thimerosal and 
the Occurrence of Autism: Negative Ecological Evidence From 
Danish Population-Based Data. Pediatrics 2003;112(3):604–606. 
doi:3 september, 2003.
Mrozek-Budzyn D, Majewska R, Kiełtyka A. Early exposure 
to thimerosal-containing vaccines and children’s cognitive 
development. A 9-year prospective birth cohort study in 
Poland. European Journal of Pediatrics. 2014;174(3):383-391. 
doi:10.1007/s00431-014-2412-5.
Offit PA, Jew RK. Addressing Parents’ Concerns: Do Vaccines 
Contain Harmful Preservatives, Adjuvants, Additives, or 
Residuals? Pediatrics 2003;112(6):1394–1397. Available at: 
http://pediatrics.aappublications.org/content/112/6/1394. 
Accessed 2015.
Petrovsky N, Aguilar J. Vaccine adjuvants: Current state and 
future trends. Immunology and Cell Biology. 2004;82(5):488-
496. doi:10.1111/j.0818-9641.2004.01272.x.
Tomljenovic, L Shaw, C.A. Do alumkinum vaccine auvants con-
tribute to the rising prevalence of autism?, J. Inorg. Biochem. 
(2011), doi:10.10.16/j.jinorgbio.2011.08.008
World Health Organization. WHO - Mercury and health. 
January 2016. Available at: http://www.who.int/mediacentre/
factsheets/fs361/en/. Accessed June 8, 2016.
World Health Organization. WHO - Mercury and health. 
September 2013. Available at: http://www.who.int/mediacentre/
factsheets/fs361/en/. Accessed December 17, 2015.
Young HA, et al., Thimerosal exposure in infants and neuro-
developmental disorders: An assessment of computerized 
medical records in the Vaccine Safety Datalink. Journal of the 
Neurological Sciences. 2008;271(1-2):110-118.doi:10.1016/j.
jns.2008.04.002.
